July 1, 2014

The inhibition of a protein opens the door to the treatment of pancreatic cancer, one of the tumours with the worst prognosis


click to expand

The identification of new therapeutic targets is urgently needed due to the ineffectiveness of current targets

Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. For the first time they have demonstrated the effects of the inhibition of this protein in mice suffering this type of cancer and the results showed an increase in survival of 20%. The work further suggests that it could be a therapeutic target with no adverse effects.